237 related articles for article (PubMed ID: 14737072)
1. A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells.
Hönemann D; Kufer P; Rimpler MM; Chatterjee M; Friedl S; Riecher F; Bommert K; Dörken B; Bargou RC
Leukemia; 2004 Mar; 18(3):636-44. PubMed ID: 14737072
[TBL] [Abstract][Full Text] [Related]
2. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
3. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
[TBL] [Abstract][Full Text] [Related]
4. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
Csóka M; Strauss G; Debatin KM; Moldenhauer G
Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
[TBL] [Abstract][Full Text] [Related]
5. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
6. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
7. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
[TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
9. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
10. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
[TBL] [Abstract][Full Text] [Related]
11. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
[TBL] [Abstract][Full Text] [Related]
12. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
13. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
[TBL] [Abstract][Full Text] [Related]
15. A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma.
Zhou Y; Gou LT; Mu B; Liao WC; He J; Ma C; Yao YQ; Yang JL
Biotechnol Lett; 2012 Jul; 34(7):1183-91. PubMed ID: 22421972
[TBL] [Abstract][Full Text] [Related]
16. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
17. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
18. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
Kuo SR; Wong L; Liu JS
Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
[TBL] [Abstract][Full Text] [Related]
19. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
20. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing.
Grosse-Hovest L; Hartlapp I; Marwan W; Brem G; Rammensee HG; Jung G
Eur J Immunol; 2003 May; 33(5):1334-40. PubMed ID: 12731059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]